6533b852fe1ef96bd12aa477
RESEARCH PRODUCT
Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophreniaspectrum disorders: Findings from the STAR Network Depot Study
Barbui CNosè MPurgato MTurrini GOstuzzi GMazzi MaPapola DGastaldon CTerlizzi SBertolini FPiccoli ARuggeri MDe Fazio PMagliocco FCaroleo MRaffaele GD'agostino AOstinelli EgChirico MCavallotti SLucii CBolognesi SDebolini SPierantozzi EFargnoli FDel Zanna MGiannini ALuccarelli LDe Capua AAnnese PmCerretini MTozzi FMagnani NCardamone GBardicchia FFacchi ESoscia FZotos SBiancosino BZonta FPompei FCallegari CZizolfi DPoloni NIelmini MCaselli IGiana EBuzzi ADiurni MMilano ASani ECalzolari RBortolaso PPiccinelli MCazzamalli SAlberini GPiantanida SCostantini CParonelli CDi Caro AMoretti VGozzi MD'ippolito CBarbanti SvPapalini ACorbo MMartinotti GCampese OFiori FLorusso MDi Capro LViceconte DMancini VSuraniti FSignorelli MsiRossi ELupoli PMenchetti MTerzi LBoso MRisaro PDe Paoli GCatania CTarricone ICaretto VStorbini VEmiliani RBalzarro BCarrà GBartoli FTabacchi TNava RBono AProvenzi MBrambilla GAspesi FTrotta GTremolada MCastagna GBava MVerrengia ELucchi SOriani MgBarchiesi MPacetti MAguglia AMagni LrRossi GBeneduce RTura GbLaffranchini LMastromo DFerrato FRestaino FMonzani EPorcellana MLimosani IGhio LFerro MParise VfBalletta GAddeo LDe Vivo EDi Benedetto RPinna FCarpiniello BSpano MGiacomin MPecile DMattei CFabrici EpPanarello SPeresson GVitucci CBonavigo TPerini GBoschello FStrizzolo SGardellin FDi Giannantonio MMoretti DFizzotti CCossetta EDi Gregorio LSozzi FBoncompagni GLa Barbera DColli GLaurenzi SCalandra CLuca MCrocamo CStar Network Depot Investigatorssubject
Aripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate; Schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Knowledge Attitudes Practice; Humans; Male; Medication Adherence; Paliperidone Palmitate; Practice Patterns Physicians'; Schizophrenia; Schizophrenic Psychology; Young AdultAdultMaleLong-acting injectable antipsychoticmedicine.medical_specialtyHealth Knowledge Attitudes Practicemedicine.medical_treatmentAripiprazole monohydrate Long-acting injectable antipsychotics Paliperidone palmitate SchizophreniaAripiprazolePractice PatternsLong-acting injectable antipsychoticsMedication Adherence03 medical and health sciencesYoung Adult0302 clinical medicineAripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate; SchizophreniaInternal medicineBrief Psychiatric Rating ScalemedicineHumansPharmacology (medical)Practice Patterns Physicians'AntipsychoticSettore MED/25 - PsichiatriaPaliperidone PalmitatePaliperidone palmitatePracticePhysicians'business.industryHealth KnowledgeAripiprazole monohydratemedicine.disease030227 psychiatryPsychiatry and Mental healthSchizophreniaAttitudesPropensity score matchingSchizophreniaObservational studyAripiprazoleFemaleSchizophrenic Psychologybusiness030217 neurology & neurosurgerymedicine.drugPsychopathologyAntipsychotic Agentsdescription
This study, based on the 'Servizi Territoriali Associati per la Ricerca' (STAR) Network Depot Study nationwide baseline data, explored whether individual symptoms severity and clusters might influence the prescription of paliperidone palmitate 1-month (PP1M) vs. aripiprazole monohydrate. The Brief Psychiatric Rating Scale (BPRS) was used to assess psychopathology and relevant symptoms clusters. Drug Attitude Inventory, 10 items, was used to test attitude towards medications. Adherence to treatments was rated according to the Kemp seven-point scale. We assessed for eligibility 451 individuals and, among them, we included 195 subjects (n = 117 who started PPM1 and n = 78 aripiprazole monohydrate). Individuals were comparable in terms of age, gender, treatment years, recent hospitalizations, previous long-acting injectable antipsychotic treatments, additional oral treatments, attitude toward drugs, medication adherence, and alcohol/substance-related comorbidities. Subjects starting PP1M presented higher BPRS overall (P = 0.009), positive (P = 0.015), and negative (P = 0.010) symptom scores compared to subjects starting aripiprazole monohydrate. Results were confirmed by appropriate regression models and propensity score matching analysis. No differences were found comparing the other BPRS subscale scores: affect, resistance, and activation. Clinicians may be more prone to prescribe PPM1, rather than aripiprazole monohydrate, to subjects showing higher overall symptom severity, including positive and negative symptoms. No additional clinical factors influenced prescribing attitudes in our sample.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-07-01 |